[1] 刘宗超,李哲轩,张阳,等. 2020全球癌症统计报告解读 [J] . 肿瘤综合治疗电子杂志,2021, 7(2):1
LIU ZC, LI ZX, ZHANG Y, et al. Interpretation on the report of Global Cancer Statistics 2020 [J].J Multidiscip Cancer Manag (Electron Ver), 2021, 7(2):1
[2] YONEDA K, IMANISHI N, ICHIKI Y, et al. Treatment of non-small cell lung cancer with EGFR-mutations [J].J UOEH, 2019, 41(2):153
[3] REIS R, LABAT L, ALLARD M, et al. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients [J].Pharm Biomed Anal, 2018, 158: 174
[4] 曹华,叶建增,孔程,等. 晚期非小细胞肺癌表皮生长因子受体-酪氨酸激酶抑制剂耐药后联合阿帕替尼治疗的初步分析 [J].肿瘤综合治疗电子杂志,2021, 7(4):62
CAO H, YE JZ, KONG C, et al. Analysis of the combination of apatinib and epidermal growth factor receptor-tyrosine kinase inhibitor for advanced non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitor resistance [J].J Multidiscip Cancer Manag(Electron Ver), 2021, 7(4):62
[5] WIND S, SCHNELL D, EBNER T, et al. Clinical pharmacokinetics and pharmacodynamics of afatinib [J].Clin Pharmacokinet, 2017, 56(3):235
[6] LI SH, LIU CY, HSU PC, et al. Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases [J].Expert Review Anticancer Ther, 2018, 18 (1):81
[7] 周彩存,程颖,王洁,等. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南[M].北京: 人民卫生出版社,2021: 55
ZHOU CC, CHENG Y, WANG J, et al. Guidelines of Chinese Society of Clinical Oncology (CSCO) Non-small Cell Cancer [M].Peking: Peoples Medical Publishing House,2021: 55
[8] SCHULER M, WU YL, HIRSH V, et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases [J].Thorac Oncol, 2016, 11(3):380
[9] ROSKOSKI RJ. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update [J].Pharmacol Res, 2020, 152: 104609
[10] NAKAMURA H, TAKAGI M. Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons [J].Surge Today, 2014, 45(11):1
[11] SOLASSOL I, PINGUET F, QUANTIN X . FDA-and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management [J].Biomolecules, 2019, 9(11):668
[12] WIND S, SCHMID M, ERHARDT J, et al. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours [J].Clin Pharmacokinet, 2013, 52: 1101
[13] VEELEN AV, GEELRV, BEER YD, et al. Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results [J].Biomed Chromatogr, 2020, 34(4):4771
[14] BELLO CL, SMITH E, RUIZ-GARCIA A, et al. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers [J].Cancer Chemother Pharmacol, 2013, 72(2):379
[15] IRIEK, SHOBU S, HIRATSUJI S, et al. Development and validation of a method for gefitinib quantification in dried blood spots using liquid chromatography-tandem mass spectrometry: application to finger-prick clinical blood samples of patients with non-small cell lung cancer [J].J Chromatogr B Analyt Technol Biomed Life Sci, 2018, 1087-1088: 1
[16] WANG ZL, LIM MY, CHIN TM, et al. Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry [J].J Chromatogr B Biomed Appl, 2011, 879(22):2155
[17] GUAN SX, CHEN X, WANG F, et al. Development and validation of a sensitive LC-MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients [J].J Pharm Biomed Anal, 2019, 172: 364
[18] GUETENS G, PRENEN H, BOECK GD, et al. Sensitive and specific quantification of the anticancer agent ZD1839 (gefitinib) in plasma by on-column focusing capillary liquid chromatography-tandem mass spectrometry [J].J Chromatogr A, 2005, 1082(1):2
[19] ZHAO M, HARTKE C, JIMENO A, et al. Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry [J].J Chromatogr B, 2005, 819(1):73
[20] ZHENGN, ZHAOC, HEXR, et al. Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study [J].J Chromatogr B Analyt Technol Biomed Life Sci, 2016, 1011: 215
[21] CHEN Y, WANG MZ, ZHONG W, et al. Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis [J].Lung Cancer, 2013, 82(2):313
[22] MAHER HM, ALZOMAN NZ, SHEHATA SM. Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetic interaction studies [J].J Pharm Biomed Analy, 2016, 124: 216
[23] NOH CK, LEE JH, KIM MS, et al. Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats [J].J Separat Sci, 2017, 40(19):3782
[24] HAYASHI H, KITA Y, LIHARA H, et al. Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer [J].Biomed Chromatogr, 2016, 30(7):1150
[25] 黄逸生,周志凌,雷丽婵,等. 高效液相色谱质谱串联法检测厄洛替尼血浆浓度 [J].中南药学,2011, 9(11):801
HUANG YS, ZHOU ZL, LEI LC, et al. Determination oferlotinibin human plasma by HPLC-MS/MS [J].Cent South Pharm, 2011, 9(11):801
[26] SVEDBERG A, GREEN H, VIKSTROM A, et al. A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethylerlotinib and semi-quantification of erlotinib metabolites in human plasma [J].J Pharmaceutical Biomed Analy, 2015, 107: 186
[27] ROOD JJM, TORANO JS, SOMOVILLA VJ, et al. Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification[J].J Chromatogr B Analyt Technol Biomed Life Sci, 2021, 1166: 122554
[28] HONEYWELL R, YARZADAH K, GIOVANNETTI E, et al. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry[J].J Chromatogr B Analyt Technol Biomed Life Sci, 2010, 878(15-16):1059
[29] ISHIDA T, NAITO T, KAWAKAMI J. Simultaneous determination of erlotinib and its isomeric major metabolites in human plasma using isocratic liquid chromatography-tandem mass spectrometry and its clinical application[J].Biomed Chromatogr, 2014, 29(5):643
[30] CHAHBOUNI A, DEN BJC, VOS RM, et al. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry[J].Ther Drug Monit, 2009, 31(6):683
[31] LANKHEET NA, SCHAAKE EE, ROSING H, et al. Quantitative determination of erlotinib and O-desmethylerlotinib in human EDTA plasma and lung tumor tissue[J].Bioanalysis, 2012, 21(4):2563
[32] LI MY, WU Q, LI HQ, et al. A sensitive LC-MS/MS method to determine the concentrations of erlotinib and its active metabolite OSI-420 in BALB/c nude mice plasma simultaneously and its application to a pharmacokinetic study[J].Chin Pharm Sci, 2012, 21(4):296
[33] HE Y, ZHOU L, GAO S, et al. Development and validation of a sensitive LC-MS/MS method for simultaneous determination of eight tyrosine kinase inhibitors and its application in mice pharmacokinetic studies[J].Pharm Biomed Anal, 2018, 148: 65
[34] 王海东. 辛伐他汀和伊曲康唑对大鼠体内厄洛替尼药代动力学的影响研究[D].石家庄: 河北医科大学, 2018
WANG HD. Effects of Simvastatin and Itraconazole on the Pharmacokinetics of Erlotinib in Rats [D].Shijiazhuang: Hebei Medical University,2018
[35] LIU DY, JIANG J, HU P, et al. Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry[J].J Chromatogr B Analyt Technol Biomed Life Sci, 2009, 877(30):3781
[36] VEERMAN GDM, LAM MH, MATHIJSSEN RHJ, et al. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: focusing on the stability of osimertinib[J].J Chromatogr B, 2019, 1113: 37
[37] REIS R, LABAT L, ALLARD M, et al. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients[J].J Pharm Biomed Anal, 2018, 158: 174
[38] QIU XJ, LIN QM, NING ZD, et al. Quantitative bioanalytical assay for the human epidermal growth factor receptor (HER) inhibitor dacomitinib in rat plasma by UPLC-MS/MS[J].J Pharm Biomed Anal, 2019, 166: 66
[39] ROOD JJM, HAREN MJV, BEIJNEN JH, et al. Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle-and desmethyl metabolites by liquid chromatography-tandem mass spectrometry[J].J Pharm Biomed Anal, 2019, 177: 112871
[40] JANSSEN JM, VRIES ND, VENEKAMP N, et al. Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma[J].J Pharm Biomed Anal, 2019, 174: 561
[41] 李力, 肖昌钱, 李贺, 等. LC-MS/MS法测定非小细胞肺癌患者血浆中奥希替尼浓度[J].中国临床药理学杂志,2019, 35(19):2381
LI L, XIAO CQ, LI H, et al. Determination of osimertinib in plasma of patients with non-small cell lung cancer by liquid chromatography tandem mass spectrometry[J].Chin J Clin Pharmacol, 2019, 35(19):2381
[42] ZHENG X, WANG WC, ZHANG YB, et al. Development and validation of a UPLC-MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma[J].J Biomed Chromatogr, 2018, 32(12):4365
[43] ROOD JJM, VAN BUSSEL MTJ, SCHELLENS JHM, et al. Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma[J].J Chromatogr B Analyt Technol Biomed Life Sci, 2016, 1031: 80
[44] XIONGS, DENGZP, SUNPL, et al. Development and validation of a rapid and sensitive LC-MS/MS method for the pharmacokinetic study of osimertinib in rats[J].Aoac Intern, 2017, 100(6):1771
[45] YING ZZ, WEI JY, LIU RJ, et al. An UPLC-MS/MS method for determination of osimertinib in rat plasma: Application to Investigating the effect of Ginsenoside Rg3 on the pharmacokinetics of osimertinib[J].Int J Anal Chem, 2020: 8814214: 9
[46] WU QJ, JIANG H, WANG SH, et al. Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats[J].Thorac Cancer, 2020, 11(10):2775
[47] RODRIGUEZ J, CASTANEDA G, MUNOZ L, et al. Simultaneous determination of erlotinib and its metabolites in human urine and serum samples by high-performance liquid chromatography[J].Chromatographia, 2017, 80: 409
[48] MENG J, ZHANG H, BAO JJ, et al. Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans[J].ActaPharmacol Sin, 2022, 43(2):494
[49] PLUMB RS, GETHINGS LA, KING A, et al. Hybrid organic/inorganic hybrid surface technology for increasing the performance of LC/MS(MS)-based drug metabolite identification studies: application to gefitinib and metabolites in mouse plasma and urine[J].Pharm Biomed Anal, 2021, 200: 114076
[50] TISEO M, ANDREOLI R, GELSOMINO F, et al. Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)[J].Lung Cancer, 2014, 83(2):265
[51] FANG L, SONG Y, WENG X, et al. Highly sensitive HPLC-DAD method for the assay of gefitinib in patient plasma and cerebrospinal fluid: application to a blood-brain barrier penetration study[J].J Biomed Chromatogr, 2015, 29: 1937
[52] CLARKE JL, PAO W, WU N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer[J].Neurooncol, 2010, 99(2):283
[53] MASUDA T, HATTORI N, HAMADA A, et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy[J].Cancer Chemother Pharmacol, 2011, 67(6):1465
[54] ZHAO J, CHEN MJ, ZHONG W, et al. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma[J].Clin Lung Cancer, 2013, 14(2):188
[55] IRIE K, NANJO S, HATA A, et al. Development of an LC-MS/MS-based method for quantitation of osimertinib in human plasma and cerebrospinal fluid[J].Bioanalysis, 2019, 11(9):847
[56] 郝少莉, 仇农学. 沉淀分离技术在蛋白质处理方面的应用[J].粮食与食品业,2007, 14(1):20
HAO SL, QIU NX. Applications of precipitation separation technologies in handling protein[J].Cereal Food Ind, 2007, 14(1):20
[57] FIALA O, HOSEK P, PESEK M, et al. Serum concentration of Erlotinib and its correlation with outcome and toxicity in patients with Advanced-stage NSCLC[J].Anticancer Res, 2017, 37(11):6469
[58] ROBERT R, TINA TL. Analytical Methods for Quantification of Drug Metabolites in Biological Samples. Chromatography-The Most Versatile Method of Chemical Analysis [M].London: Intech Open, 2012: 40383
[59] RETMANA IA, BEIJNEN JH, SPARIDANS RW. Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites[J].J Chromatogr B Analyt Technol Biomed Life Sci, 2021, 1162: 122466
[60] 吴迪,陈华,王腾,等. 19F核磁共振定量法测定吉非替尼的含量[J].中国新药杂志,2017, 26(19):2343
WU D, CHEN H, WANG T, et al. Determination of gefitinib by19F QNMR[J].Chin J New Drugs, 2017, 26(19):2343
